Related Experiment Video
Updated: May 10, 2025
23:53
Ole Isacson: Development of New Therapies for Parkinson's Disease
Published on: April 29, 2007
7.9K
[Emerging disease-modifying therapies for Parkinson's disease]
Anne-Laure Mahul-Mellier1, Cécile Hubsch2, Mayté Castro2
1Laboratoire UPDANGELO, Institut de bioingénierie et Institut de santé globale, École polytechnique fédérale de Lausanne, 1015 Lausanne.
Revue Medicale Suisse
|April 25, 2025
Summary
Current Parkinson's disease (PD) treatments manage symptoms, not progression. New research explores immunotherapy, gene therapy, cell therapy, GLP-1 analogues, and gut microbiota modulation for disease modification.
Area of Science:
- Neuroscience
- Pharmacology
- Biotechnology
Background:
- Parkinson's disease (PD) lacks disease-modifying treatments despite extensive research.
- Understanding neurodegenerative mechanisms in PD has revealed novel therapeutic targets.
- Pathological protein aggregation and dopaminergic neuron loss are key PD features.
Purpose of the Study:
- To review key strategies currently under investigation for Parkinson's disease treatment.
- To highlight advances in understanding PD neurodegeneration and potential therapeutic targets.
- To discuss emerging therapies aimed at modifying PD progression.
Main Methods:
- Review of current scientific literature on Parkinson's disease therapeutics.
- Analysis of emerging strategies including immunotherapy, gene therapy, and cell therapy.
- Exploration of neuroprotective agents like GLP-1 analogues and gut microbiota modulation.
Main Results:
- Several novel therapeutic strategies show promise for altering PD progression.
- Immunotherapy, antisense oligonucleotides, and siRNA target pathological protein aggregation.
- Cell therapy aims to restore dopaminergic neurons, while GLP-1 analogues offer neuroprotection.
Conclusions:
- Advances in understanding PD mechanisms are driving hope for effective treatments.
- Targeting protein aggregation, neuron loss, and neuroprotection are key therapeutic avenues.
- Investigational strategies offer potential for disease modification in Parkinson's disease.
Related Concept Videos
01:24Parkinson's Disease: Treatment
148
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
148
01:15Parkinson's Disease: Overview
310
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
310
01:22Alzheimer's Disease: Treatment
128
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
128
01:28Drug Therapy
28
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
28
01:21EPS and iPS Cells in Disease Research
2.7K
Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...
2.7K
01:37Neural Regulation
39.0K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.0K